{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:20:02Z","timestamp":1791685202469,"version":"4.3.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"SERB-SIRE","award":["SIR\/2022\/000286"],"award-info":[{"award-number":["SIR\/2022\/000286"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10787-024-01549-1","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T02:02:35Z","timestamp":1723514555000},"page":"2801-2820","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Unraveling neuroprotection in Parkinson\u2019s disease: Nrf2\u2013Keap1 pathway\u2019s vital role amidst pathogenic pathways"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-7575","authenticated-orcid":false,"given":"Tanzeer","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Choubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Kaasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"1549_CR1","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.freeradbiomed.2013.08.190","volume":"65","author":"A Alfieri","year":"2013","unstructured":"Alfieri A, Srivastava S, Siow RCM et al (2013) Sulforaphane preconditioning of the Nrf2\/HO-1 defense pathway protects the cerebral vasculature against blood-brain barrier disruption and neurological deficits in stroke. Free Radic Biol Med 65:1012\u20131022. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.08.190","journal-title":"Free Radic Biol Med"},{"key":"1549_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00496-y","author":"P Alvarez Jerez","year":"2023","unstructured":"Alvarez Jerez P, Alcantud JL, de los Reyes-Ram\u00edrez L et al (2023) Exploring the genetic and genomic connection underlying neurodegeneration with brain iron accumulation and the risk for Parkinson\u2019s disease. npj Park Dis. https:\/\/doi.org\/10.1038\/s41531-023-00496-y","journal-title":"npj Park Dis"},{"key":"1549_CR3","doi-asserted-by":"publisher","first-page":"964","DOI":"10.14336\/AD.2021.0511","volume":"12","author":"A Anandhan","year":"2021","unstructured":"Anandhan A, Nguyen N, Syal A et al (2021) NRF2 loss accentuates parkinsonian pathology and behavioral dysfunction in human \u03b1-synuclein overexpressing mice. Aging Dis 12:964\u2013982. https:\/\/doi.org\/10.14336\/AD.2021.0511","journal-title":"Aging Dis"},{"key":"1549_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/cdd.2012.81","volume":"20","author":"G Ashrafi","year":"2013","unstructured":"Ashrafi G, Schwarz TL (2013) The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ 20:31\u201342. https:\/\/doi.org\/10.1038\/cdd.2012.81","journal-title":"Cell Death Differ"},{"key":"1549_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1566524019666191016150757","volume":"20","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Ahmadi Z, Mohammadinejad R et al (2020) Curcumin activates the Nrf2 pathway and induces cellular protection against oxidative injury. Curr Mol Med 20:116\u2013133. https:\/\/doi.org\/10.2174\/1566524019666191016150757","journal-title":"Curr Mol Med"},{"key":"1549_CR6","doi-asserted-by":"publisher","unstructured":"Baird L, Yamamoto M (2020) The molecular mechanisms regulating the keap1-nrf2 pathway. Mol Cell Biol 40. https:\/\/doi.org\/10.1128\/MCB.00099-20","DOI":"10.1128\/MCB.00099-20"},{"key":"1549_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-020-00408-1","volume":"15","author":"K Belarbi","year":"2020","unstructured":"Belarbi K, Cuvelier E, Bonte MA et al (2020) Glycosphingolipids and neuroinflammation in Parkinson\u2019s disease. Mol Neurodegener 15:1\u201316. https:\/\/doi.org\/10.1186\/s13024-020-00408-1","journal-title":"Mol Neurodegener"},{"key":"1549_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbamcr.2018.02.010","volume":"1865","author":"I Bellezza","year":"2018","unstructured":"Bellezza I, Giambanco I, Minelli A, Donato R (2018) Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res 1865:721\u2013733. https:\/\/doi.org\/10.1016\/j.bbamcr.2018.02.010","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1549_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U et al (2004) Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res 318:121\u2013134. https:\/\/doi.org\/10.1007\/s00441-004-0956-9","journal-title":"Cell Tissue Res"},{"key":"1549_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1264842","volume":"14","author":"G Bresciani","year":"2023","unstructured":"Bresciani G, Manai F, Davinelli S et al (2023) Novel potential pharmacological applications of dimethyl fumarate\u2014an overview and update. Front Pharmacol 14:1\u201319. https:\/\/doi.org\/10.3389\/fphar.2023.1264842","journal-title":"Front Pharmacol"},{"key":"1549_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00702-016-1633-3","volume":"124","author":"PA Broderick","year":"2017","unstructured":"Broderick PA, Wenning L, Li YS (2017) Neuromolecular imaging, a nanobiotechnology for Parkinson\u2019s disease: advancing pharmacotherapy for personalized medicine. J Neural Transm 124:57\u201378. https:\/\/doi.org\/10.1007\/s00702-016-1633-3","journal-title":"J Neural Transm"},{"key":"1549_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/jnnp.68.6.685","volume":"68","author":"DJ Brooks","year":"2000","unstructured":"Brooks DJ (2000) Dopamine agonists: their role in the treatment of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatr 68:685\u2013689. https:\/\/doi.org\/10.1136\/jnnp.68.6.685","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"1549_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11139-3","author":"KE Carlstr\u00f6m","year":"2019","unstructured":"Carlstr\u00f6m KE, Ewing E, Granqvist M et al (2019) Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-019-11139-3","journal-title":"Nat Commun"},{"key":"1549_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/JPD-202221","volume":"11","author":"AM Castonguay","year":"2021","unstructured":"Castonguay AM, Gravel C, L\u00e9vesque M (2021) Treating Parkinson\u2019s disease with antibodies: previous studies and future directions. J Parkinsons Dis 11:71\u201392. https:\/\/doi.org\/10.3233\/JPD-202221","journal-title":"J Parkinsons Dis"},{"key":"1549_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JPD-191683","volume":"9","author":"S Cerri","year":"2019","unstructured":"Cerri S, Mus L, Blandini F (2019) Parkinson\u2019s disease in women and men: what\u2019s the difference? J Parkinsons Dis 9:501\u2013515. https:\/\/doi.org\/10.3233\/JPD-191683","journal-title":"J Parkinsons Dis"},{"key":"1549_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105325","volume":"156","author":"A Chakkittukandiyil","year":"2022","unstructured":"Chakkittukandiyil A, Sajini DV, Karuppaiah A, Selvaraj D (2022) The principal molecular mechanisms behind the activation of Keap1\/Nrf2\/ARE pathway leading to neuroprotective action in Parkinson\u2019s disease. Neurochem Int 156:105325. https:\/\/doi.org\/10.1016\/j.neuint.2022.105325","journal-title":"Neurochem Int"},{"key":"1549_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.freeradbiomed.2019.06.024","volume":"141","author":"B Chen","year":"2019","unstructured":"Chen B, Wen X, Jiang H et al (2019) Interactions between iron and \u03b1-synuclein pathology in Parkinson\u2019s disease. Free Radic Biol Med 141:253\u2013260. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2019.06.024","journal-title":"Free Radic Biol Med"},{"key":"1549_CR19","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41593-022-01140-3","volume":"25","author":"ML Choi","year":"2022","unstructured":"Choi ML, Chappard A, Singh BP et al (2022) Pathological structural conversion of \u03b1-synuclein at the mitochondria induces neuronal toxicity. Nat Neurosci 25:1134\u20131148. https:\/\/doi.org\/10.1038\/s41593-022-01140-3","journal-title":"Nat Neurosci"},{"key":"1549_CR20","doi-asserted-by":"publisher","first-page":"ITC5-1","DOI":"10.7326\/0003-4819-157-9-201211060-01005","volume":"157","author":"KL Chou","year":"2012","unstructured":"Chou KL (2012) In the clinic. Parkinson disease. Ann Intern Med 157:ITC5-1-ITC5-16. https:\/\/doi.org\/10.7326\/0003-4819-157-9-201211060-01005","journal-title":"Ann Intern Med"},{"key":"1549_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neulet.2018.04.004","volume":"697","author":"CT Chu","year":"2019","unstructured":"Chu CT (2019) Multiple pathways for mitophagy: a neurodegenerative conundrum for Parkinson\u2019s disease. Neurosci Lett 697:66\u201371. https:\/\/doi.org\/10.1016\/j.neulet.2018.04.004","journal-title":"Neurosci Lett"},{"key":"1549_CR22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.014294","volume":"296","author":"EH Clark","year":"2021","unstructured":"Clark EH, de la Torre AV, Hoshikawa T, Briston T (2021) Targeting mitophagy in Parkinson\u2019s disease. J Biol Chem 296:100209. https:\/\/doi.org\/10.1074\/jbc.REV120.014294","journal-title":"J Biol Chem"},{"key":"1549_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1124\/pr.117.014753","volume":"70","author":"A Cuadrado","year":"2018","unstructured":"Cuadrado A, Manda G, Hassan A et al (2018) Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach. Pharmacol Rev 70:348\u2013383. https:\/\/doi.org\/10.1124\/pr.117.014753","journal-title":"Pharmacol Rev"},{"key":"1549_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/genes12071006","author":"JO Day","year":"2021","unstructured":"Day JO, Mullin S (2021) The genetics of Parkinson\u2019s disease and implications for clinical practice. Genes. https:\/\/doi.org\/10.3390\/genes12071006","journal-title":"Genes"},{"key":"1549_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40478-021-01209-3","volume":"9","author":"A Delaidelli","year":"2021","unstructured":"Delaidelli A, Richner M, Jiang L et al (2021a) \u03b1-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response. Acta Neuropathol Commun 9:105. https:\/\/doi.org\/10.1186\/s40478-021-01209-3","journal-title":"Acta Neuropathol Commun"},{"key":"1549_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104756","volume":"138","author":"F Dernie","year":"2020","unstructured":"Dernie F (2020) Mitophagy in Parkinson\u2019s disease: From pathogenesis to treatment target. Neurochem Int 138:104756. https:\/\/doi.org\/10.1016\/j.neuint.2020.104756","journal-title":"Neurochem Int"},{"key":"1549_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12551-016-0244-4","volume":"9","author":"P Deshmukh","year":"2017","unstructured":"Deshmukh P, Unni S, Krishnappa G, Padmanabhan B (2017) The Keap1\u2013Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev 9:41\u201356. https:\/\/doi.org\/10.1007\/s12551-016-0244-4","journal-title":"Biophys Rev"},{"key":"1549_CR29","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/j.1471-4159.1989.tb07264.x","volume":"52","author":"DT Dexter","year":"1989","unstructured":"Dexter DT, Wells FR, Lees AJ et al (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson\u2019s disease. J Neurochem 52:1830\u20131836. https:\/\/doi.org\/10.1111\/j.1471-4159.1989.tb07264.x","journal-title":"J Neurochem"},{"key":"1549_CR30","first-page":"321","volume":"54","author":"BS Dhaware","year":"2000","unstructured":"Dhaware BS, Balsara JJ, Nandal NV, Chandorkar AG (2000) Effects of amantadine on modification of dopamine dependent behaviours by molindone. Indian J Med Sci 54:321\u2013324","journal-title":"Indian J Med Sci"},{"key":"1549_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41580-018-0003-4","volume":"19","author":"I Dikic","year":"2018","unstructured":"Dikic I, Elazar Z (2018) Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol 19:349\u2013364. https:\/\/doi.org\/10.1038\/s41580-018-0003-4","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1549_CR32","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1111\/febs.14379","volume":"285","author":"AT Dinkova-Kostova","year":"2018","unstructured":"Dinkova-Kostova AT, Kostov RV, Kazantsev AG (2018) The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS J 285:3576\u20133590. https:\/\/doi.org\/10.1111\/febs.14379","journal-title":"FEBS J"},{"key":"1549_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-33252-6","volume":"13","author":"D Emin","year":"2022","unstructured":"Emin D, Zhang YP, Lobanova E et al (2022) Small soluble \u03b1-synuclein aggregates are the toxic species in Parkinson\u2019s disease. Nat Commun 13:1\u201315. https:\/\/doi.org\/10.1038\/s41467-022-33252-6","journal-title":"Nat Commun"},{"key":"1549_CR34","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/mds.26048","volume":"29","author":"AJ Espay","year":"2014","unstructured":"Espay AJ, Lewitt PA, Kaufmann H (2014) Norepinephrine deficiency in Parkinson\u2019s disease: the case for noradrenergic enhancement. Mov Disord 29:1710\u20131719. https:\/\/doi.org\/10.1002\/mds.26048","journal-title":"Mov Disord"},{"key":"1549_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110234","volume":"127","author":"T Farkhondeh","year":"2020","unstructured":"Farkhondeh T, Folgado SL, Pourbagher-Shahri AM et al (2020) The therapeutic effect of resveratrol: focusing on the Nrf2 signaling pathway. Biomed Pharmacother 127:110234. https:\/\/doi.org\/10.1016\/j.biopha.2020.110234","journal-title":"Biomed Pharmacother"},{"key":"1549_CR36","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1016\/j.jmb.2019.10.015","volume":"432","author":"LE Fritsch","year":"2020","unstructured":"Fritsch LE, Moore ME, Sarraf SA, Pickrell AM (2020) Ubiquitin and receptor-dependent mitophagy pathways and their implication in neurodegeneration. J Mol Biol 432:2510\u20132524. https:\/\/doi.org\/10.1016\/j.jmb.2019.10.015","journal-title":"J Mol Biol"},{"key":"1549_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0891988720988904","volume":"35","author":"R Gilbert","year":"2022","unstructured":"Gilbert R, Khemani P (2022) Treatment of advanced Parkinson\u2019s disease. J Geriatr Psychiatr Neurol 35:12\u201323. https:\/\/doi.org\/10.1177\/0891988720988904","journal-title":"J Geriatr Psychiatr Neurol"},{"key":"1549_CR38","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s11064-018-02711-2","volume":"44","author":"AP Gureev","year":"2019","unstructured":"Gureev AP, Popov VN (2019) Nrf2\/ARE pathway as a therapeutic target for the treatment of Parkinson diseases. Neurochem Res 44:2273\u20132279. https:\/\/doi.org\/10.1007\/s11064-018-02711-2","journal-title":"Neurochem Res"},{"key":"1549_CR39","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.cell.2022.05.008","volume":"185","author":"E Hallacli","year":"2022","unstructured":"Hallacli E, Kayatekin C, Nazeen S et al (2022) The Parkinson\u2019s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. Cell 185:2035-2056.e33. https:\/\/doi.org\/10.1016\/j.cell.2022.05.008","journal-title":"Cell"},{"key":"1549_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","volume":"39","author":"JD Hayes","year":"2014","unstructured":"Hayes JD, Dinkova-Kostova AT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39:199\u2013218. https:\/\/doi.org\/10.1016\/j.tibs.2014.02.002","journal-title":"Trends Biochem Sci"},{"key":"1549_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.biocel.2013.02.012","volume":"45","author":"Q He","year":"2013","unstructured":"He Q, Song N, Jia F et al (2013) Role of \u03b1-synuclein aggregation and the nuclear factor E2-related factor 2\/heme oxygenase-1 pathway in iron-induced neurotoxicity. Int J Biochem Cell Biol 45:1019\u20131030. https:\/\/doi.org\/10.1016\/j.biocel.2013.02.012","journal-title":"Int J Biochem Cell Biol"},{"key":"1549_CR42","doi-asserted-by":"publisher","first-page":"7857186","DOI":"10.1155\/2016\/7857186","volume":"2016","author":"CA Houghton","year":"2016","unstructured":"Houghton CA, Fassett RG, Coombes JS (2016) Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician\u2019s expectation be matched by the reality? Oxid Med Cell Longev 2016:7857186. https:\/\/doi.org\/10.1155\/2016\/7857186","journal-title":"Oxid Med Cell Longev"},{"key":"1549_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3164\/jcbn.14-134","volume":"56","author":"K Itoh","year":"2015","unstructured":"Itoh K, Ye P, Matsumiya T et al (2015) Emerging functional cross-talk between the Keap1-Nrf2 system and mitochondria. J Clin Biochem Nutr 56:91\u201397. https:\/\/doi.org\/10.3164\/jcbn.14-134","journal-title":"J Clin Biochem Nutr"},{"key":"1549_CR44","doi-asserted-by":"publisher","first-page":"171","DOI":"10.22074\/ijfs.2020.44411","volume":"14","author":"R Jannatifar","year":"2020","unstructured":"Jannatifar R, Parivar K, Hayati Roodbari N, Nasr-Esfahani MH (2020) The effect of N-acetyl-cysteine on NRF2 Antioxidant gene expression in asthenoteratozoospermia men: a clinical trial study. Int J Fertil Steril 14:171\u2013175. https:\/\/doi.org\/10.22074\/ijfs.2020.44411","journal-title":"Int J Fertil Steril"},{"key":"1549_CR45","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamaneurol.2021.1335","volume":"78","author":"S Jo","year":"2021","unstructured":"Jo S, Kim Y-J, Park KW et al (2021) Association of NO2 and other air pollution exposures with the risk of Parkinson disease. JAMA Neurol 78:800\u2013808. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1335","journal-title":"JAMA Neurol"},{"key":"1549_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/1756285613493469","volume":"7","author":"DR Jones","year":"2014","unstructured":"Jones DR, Moussaud S, Mclean P (2014) Targeting heat shock proteins to modulate \u03b1-synuclein toxicity. Ther Adv Neurol Disord 7:33\u201351. https:\/\/doi.org\/10.1177\/1756285613493469","journal-title":"Ther Adv Neurol Disord"},{"key":"1549_CR47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/sj.embor.7400188","volume":"5","author":"PJ Kahle","year":"2004","unstructured":"Kahle PJ, Haass C (2004) How does parkin ligate ubiquitin to Parkinson\u2019s disease? EMBO Rep 5:681\u2013685. https:\/\/doi.org\/10.1038\/sj.embor.7400188","journal-title":"EMBO Rep"},{"key":"1549_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.46.120604.141046","volume":"47","author":"TW Kensler","year":"2007","unstructured":"Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89\u2013116. https:\/\/doi.org\/10.1146\/annurev.pharmtox.46.120604.141046","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1549_CR49","doi-asserted-by":"publisher","first-page":"107989","DOI":"10.1016\/j.neuropharm.2020.107989","volume":"167","author":"S Kim","year":"2020","unstructured":"Kim S, Indu Viswanath AN, Park J-H et al (2020) Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson\u2019s disease animal model. Neuropharmacology 167:107989. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107989","journal-title":"Neuropharmacology"},{"key":"1549_CR50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.bbrc.2015.08.016","volume":"465","author":"RV Kostov","year":"2015","unstructured":"Kostov RV, Knatko EV, McLaughlin LA et al (2015) Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. Biochem Biophys Res Commun 465:402\u2013407. https:\/\/doi.org\/10.1016\/j.bbrc.2015.08.016","journal-title":"Biochem Biophys Res Commun"},{"key":"1549_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38\u201348","journal-title":"Nat Rev Neurosci"},{"key":"1549_CR52","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.devcel.2011.12.014","volume":"22","author":"M Lazarou","year":"2012","unstructured":"Lazarou M, Jin SM, Kane LA, Youle RJ (2012) Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin. Dev Cell 22:320\u2013333. https:\/\/doi.org\/10.1016\/j.devcel.2011.12.014","journal-title":"Dev Cell"},{"key":"1549_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/mc.20465","volume":"48","author":"W Li","year":"2009","unstructured":"Li W, Kong A-N (2009) Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 48:91\u2013104. https:\/\/doi.org\/10.1002\/mc.20465","journal-title":"Mol Carcinog"},{"key":"1549_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2091-8-S1-S13","volume":"8","author":"KL Lim","year":"2007","unstructured":"Lim KL, Tan JMM (2007) Role of the ubiquitin proteasome system in Parkinson\u2019s disease. BMC Biochem 8:1\u201310. https:\/\/doi.org\/10.1186\/1471-2091-8-S1-S13","journal-title":"BMC Biochem"},{"key":"1549_CR55","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/hmg\/ddy365","volume":"28","author":"X Liu","year":"2018","unstructured":"Liu X, Hebron M, Shi W et al (2018) Ubiquitin specific protease-13 independently regulates parkin ubiquitination and alpha-synuclein clearance in alpha-synucleinopathies. Hum Mol Genet 28:548\u2013560. https:\/\/doi.org\/10.1093\/hmg\/ddy365","journal-title":"Hum Mol Genet"},{"key":"1549_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells8070712","volume":"8","author":"J Liu","year":"2019","unstructured":"Liu J, Liu W, Li R, Yang H (2019) Mitophagy in Parkinson\u2019s disease: from pathogenesis to treatment. Cells 8:1\u201319. https:\/\/doi.org\/10.3390\/cells8070712","journal-title":"Cells"},{"key":"1549_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2023.101770","volume":"49","author":"H Liu","year":"2023","unstructured":"Liu H, Zheng Q, Yuan J et al (2023) Modulating SQSTM1\/p62-dependent selective autophagy of neurons by activating Nrf2 with multifunctional nanoparticles to eliminate \u03b1-synuclein aggregates and boost therapy of Parkinson\u2019s disease. Nano Today 49:101770. https:\/\/doi.org\/10.1016\/j.nantod.2023.101770","journal-title":"Nano Today"},{"key":"1549_CR58","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12264-017-0183-5","volume":"33","author":"S Lotankar","year":"2017","unstructured":"Lotankar S, Prabhavalkar KS, Bhatt LK (2017) Biomarkers for Parkinson\u2019s disease: recent advancement. Neurosci Bull 33:585\u2013597. https:\/\/doi.org\/10.1007\/s12264-017-0183-5","journal-title":"Neurosci Bull"},{"issue":"4","key":"1549_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a009357","volume":"2","author":"MA Lynch-day","year":"2012","unstructured":"Lynch-day MA, Mao K, Wang K et al (2012) The role of autophagy in Parkinson\u2019 s disease the role of autophagy in Parkinson\u2019 s disease. Cold Spring Harb Perspect Med 2(4):1\u201314","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1549_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/life11080804","author":"L Magistrelli","year":"2021","unstructured":"Magistrelli L, Contaldi E, Comi C (2021) The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson\u2019s Disease. Life. https:\/\/doi.org\/10.3390\/life11080804","journal-title":"Life"},{"key":"1549_CR61","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.molbrainres.2004.09.014","volume":"134","author":"KA Maguire-Zeiss","year":"2005","unstructured":"Maguire-Zeiss KA, Short DW, Federoff HJ (2005) Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson\u2019s disease? Mol Brain Res 134:18\u201323. https:\/\/doi.org\/10.1016\/j.molbrainres.2004.09.014","journal-title":"Mol Brain Res"},{"key":"1549_CR62","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tibs.2020.11.007","volume":"46","author":"AB Malpartida","year":"2021","unstructured":"Malpartida AB, Williamson M, Narendra DP et al (2021) Mitochondrial dysfunction and mitophagy in Parkinson\u2019s disease: from mechanism to therapy. Trends Biochem Sci 46:329\u2013343. https:\/\/doi.org\/10.1016\/j.tibs.2020.11.007","journal-title":"Trends Biochem Sci"},{"key":"1549_CR63","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/09540260020002497","volume":"12","author":"AS Mandir","year":"2000","unstructured":"Mandir AS, Vaughan C (2000) Pathophysiology of Parkinson\u2019s disease. Int Rev Psychiatr 12:270\u2013280. https:\/\/doi.org\/10.1080\/09540260020002497","journal-title":"Int Rev Psychiatr"},{"key":"1549_CR64","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1042\/BST20211107","volume":"50","author":"S Masaldan","year":"2022","unstructured":"Masaldan S, Callegari S, Dewson G (2022) Therapeutic targeting of mitophagy in Parkinson\u2019s disease. Biochem Soc Trans 50:783\u2013797. https:\/\/doi.org\/10.1042\/BST20211107","journal-title":"Biochem Soc Trans"},{"key":"1549_CR65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature25986","volume":"556","author":"EL Mills","year":"2018","unstructured":"Mills EL, Ryan DG, Prag HA et al (2018) Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 556:113\u2013117. https:\/\/doi.org\/10.1038\/nature25986","journal-title":"Nature"},{"key":"1549_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0142438","volume":"10","author":"H Murata","year":"2015","unstructured":"Murata H, Takamatsu H, Liu S et al (2015) NRF2 Regulates PINK1 Expression under oxidative stress conditions. PLoS One 10:1\u201315. https:\/\/doi.org\/10.1371\/journal.pone.0142438","journal-title":"PLoS One"},{"key":"1549_CR67","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/mds.28922","volume":"37","author":"H Murata","year":"2022","unstructured":"Murata H, Barnhill LM, Bronstein JM (2022) Air pollution and the risk of Parkinson\u2019s disease: a review. Mov Disord 37:894\u2013904. https:\/\/doi.org\/10.1002\/mds.28922","journal-title":"Mov Disord"},{"key":"1549_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19010026","volume":"19","author":"YS Oh","year":"2018","unstructured":"Oh YS, Jun HS (2018) Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. Int J Mol Sci 19:1\u201316. https:\/\/doi.org\/10.3390\/ijms19010026","journal-title":"Int J Mol Sci"},{"key":"1549_CR69","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1002\/mds.21013","volume":"21","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, McNaught KSP (2006) Ubiquitin-proteasome system and Parkinson\u2019s disease. Mov Disord 21:1806\u20131823. https:\/\/doi.org\/10.1002\/mds.21013","journal-title":"Mov Disord"},{"key":"1549_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphys.2012.00297","volume":"3","author":"C Pacheco","year":"2012","unstructured":"Pacheco C, Aguayo LG, Opazo C (2012) An extracellular mechanism that can explain the neur effects of \u03b1-synuclein aggregates in the brain. Front Physiol 3:1\u201310. https:\/\/doi.org\/10.3389\/fphys.2012.00297","journal-title":"Front Physiol"},{"key":"1549_CR71","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/878030","author":"S Petri","year":"2012","unstructured":"Petri S, K\u00f6rner S, Kiaei M (2012) Nrf2\/ARE signaling pathway: Key mediator in oxidative stress and potential therapeutic target in ALS. Neurol Res Int. https:\/\/doi.org\/10.1155\/2012\/878030","journal-title":"Neurol Res Int"},{"key":"1549_CR72","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1124\/pr.110.003269.Abstract","volume":"63","author":"M Quik","year":"2011","unstructured":"Quik M, Wonnacott S (2011) Drug targets for Parkinson\u2019 s disease. Pharmacol Rev 63:938\u2013966. https:\/\/doi.org\/10.1124\/pr.110.003269.Abstract","journal-title":"Pharmacol Rev"},{"key":"1549_CR73","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/DDDT.S193889","volume":"13","author":"SA Reisman","year":"2019","unstructured":"Reisman SA, Gahir SS, Lee C-YI et al (2019) Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates. Drug Des Devel Ther 13:1259\u20131270. https:\/\/doi.org\/10.2147\/DDDT.S193889","journal-title":"Drug Des Devel Ther"},{"key":"1549_CR74","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1474-4422(18)30355-7","volume":"17","author":"WA Rocca","year":"2018","unstructured":"Rocca WA (2018) The burden of Parkinson\u2019s disease: a worldwide perspective. Lancet Neurol 17:928\u2013929. https:\/\/doi.org\/10.1016\/S1474-4422(18)30355-7","journal-title":"Lancet Neurol"},{"key":"1549_CR75","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1471-4159.2007.05039.x","volume":"104","author":"T Satoh","year":"2008","unstructured":"Satoh T, Kosaka K, Itoh K et al (2008) Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1\/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J Neurochem 104:1116\u20131131. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05039.x","journal-title":"J Neurochem"},{"key":"1549_CR76","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","volume":"120","author":"WJ Schulz-Schaeffer","year":"2010","unstructured":"Schulz-Schaeffer WJ (2010) The synaptic pathology of \u03b1-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Acta Neuropathol 120:131\u2013143. https:\/\/doi.org\/10.1007\/s00401-010-0711-0","journal-title":"Acta Neuropathol"},{"key":"1549_CR77","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1042\/BST20190236","volume":"49","author":"F Singh","year":"2021","unstructured":"Singh F, Ganley IG (2021) Parkinson\u2019s disease and mitophagy: an emerging role for LRRK2. Biochem Soc Trans 49:551\u2013562. https:\/\/doi.org\/10.1042\/BST20190236","journal-title":"Biochem Soc Trans"},{"key":"1549_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19010364","author":"P Sivanandy","year":"2022","unstructured":"Sivanandy P, Leey TC, Xiang TC et al (2022) Systemic review on Parkinson\u2019s disease medications, emphasizing on three recently approved drugs to control Parkinson\u2019s symptoms. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph19010364","journal-title":"Int J Environ Res Public Health"},{"key":"1549_CR79","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1073\/pnas.1522872114","volume":"114","author":"G Skibinski","year":"2017","unstructured":"Skibinski G, Hwang V, Ando DM et al (2017) Nrf2 mitigates LRRK2- and \u03b1-synuclein-induced neurodegeneration by modulating proteostasis. Proc Natl Acad Sci U S A 114:1165\u20131170. https:\/\/doi.org\/10.1073\/pnas.1522872114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1549_CR80","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1471-4159.1991.tb02017.x","volume":"56","author":"E Sofic","year":"1991","unstructured":"Sofic E, Paulus W, Jellinger K et al (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56:978\u2013982. https:\/\/doi.org\/10.1111\/j.1471-4159.1991.tb02017.x","journal-title":"J Neurochem"},{"key":"1549_CR81","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1471-4159.2009.06165.x","volume":"110","author":"W Song","year":"2009","unstructured":"Song W, Patel A, Qureshi HY et al (2009) The Parkinson disease-associated A30P mutation stabilizes alpha-synuclein against proteasomal degradation triggered by heme oxygenase-1 over-expression in human neuroblastoma cells. J Neurochem 110:719\u2013733. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06165.x","journal-title":"J Neurochem"},{"issue":"2","key":"1549_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L (2012) \u03b1-Synuclein in Parkinson\u2019 s disease. Cold Spring Harb Perspect Med 2(2):1\u201324","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1549_CR83","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.tibs.2018.11.005","volume":"44","author":"AD Stephens","year":"2019","unstructured":"Stephens AD, Zacharopoulou M, Kaminski Schierle GS (2019) The cellular environment affects monomeric \u03b1-synuclein structure. Trends Biochem Sci 44:453\u2013466. https:\/\/doi.org\/10.1016\/j.tibs.2018.11.005","journal-title":"Trends Biochem Sci"},{"key":"1549_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910251","author":"V Sukhorukov","year":"2021","unstructured":"Sukhorukov V, Voronkov D, Baranich T et al (2021) Impaired mitophagy in neurons and glial cells during aging and age-related disorders. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms221910251","journal-title":"Int J Mol Sci"},{"key":"1549_CR85","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.freeradbiomed.2017.04.365","volume":"108","author":"W Sun","year":"2017","unstructured":"Sun W, Liu X, Zhang H et al (2017) Epigallocatechin gallate upregulates NRF2 to prevent diabetic nephropathy via disabling KEAP1. Free Radic Biol Med 108:840\u2013857. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.04.365","journal-title":"Free Radic Biol Med"},{"key":"1549_CR86","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.freeradbiomed.2015.06.006","volume":"88","author":"T Suzuki","year":"2015","unstructured":"Suzuki T, Yamamoto M (2015) Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med 88:93\u2013100. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.06.006","journal-title":"Free Radic Biol Med"},{"key":"1549_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00018-022-04240-2","volume":"79","author":"GK Tofaris","year":"2022","unstructured":"Tofaris GK (2022) Initiation and progression of \u03b1-synuclein pathology in Parkinson\u2019s disease. Cell Mol Life Sci 79:1\u201311. https:\/\/doi.org\/10.1007\/s00018-022-04240-2","journal-title":"Cell Mol Life Sci"},{"key":"1549_CR88","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol 20:385\u2013397. https:\/\/doi.org\/10.1016\/S1474-4422(21)00030-2","journal-title":"Lancet Neurol"},{"key":"1549_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2018.00860","volume":"9","author":"P Troncoso-Escudero","year":"2018","unstructured":"Troncoso-Escudero P, Parra A, Nassif M, Vidal RL (2018) Outside in: UNRAVELING the role of neuroinflammation in the progression of Parkinson\u2019s disease. Front Neurol 9:1\u201315. https:\/\/doi.org\/10.3389\/fneur.2018.00860","journal-title":"Front Neurol"},{"key":"1549_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111732","author":"M Vidovi\u0107","year":"2022","unstructured":"Vidovi\u0107 M, Rikalovic MG (2022) Alpha-synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches. Cells. https:\/\/doi.org\/10.3390\/cells11111732","journal-title":"Cells"},{"key":"1549_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10071069","author":"F Villavicencio Tejo","year":"2021","unstructured":"Villavicencio Tejo F, Quintanilla RA (2021) Contribution of the nrf2 pathway on oxidative damage and mitochondrial failure in Parkinson and Alzheimer\u2019s disease. Antioxidants. https:\/\/doi.org\/10.3390\/antiox10071069","journal-title":"Antioxidants"},{"key":"1549_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener 4:1\u20139. https:\/\/doi.org\/10.1186\/s40035-015-0042-0","journal-title":"Transl Neurodegener"},{"key":"1549_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","volume":"6","author":"W Yang","year":"2020","unstructured":"Yang W, Hamilton JL, Kopil C et al (2020) Current and projected future economic burden of Parkinson\u2019s disease in the U.S. NPJ Park Dis 6:15. https:\/\/doi.org\/10.1038\/s41531-020-0117-1","journal-title":"NPJ Park Dis"},{"key":"1549_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114739","volume":"283","author":"S Yang","year":"2022","unstructured":"Yang S, Li F, Lu S et al (2022a) Ginseng root extract attenuates inflammation by inhibiting the MAPK\/NF-\u03baB signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo. J Ethnopharmacol 283:114739. https:\/\/doi.org\/10.1016\/j.jep.2021.114739","journal-title":"J Ethnopharmacol"},{"key":"1549_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.919233","volume":"13","author":"XX Yang","year":"2022","unstructured":"Yang XX, Yang R, Zhang F (2022b) Role of Nrf2 in Parkinson\u2019s disease: toward new perspectives. Front Pharmacol 13:1\u201312. https:\/\/doi.org\/10.3389\/fphar.2022.919233","journal-title":"Front Pharmacol"},{"key":"1549_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2021.655819","volume":"9","author":"L Yao","year":"2021","unstructured":"Yao L, Wu J, Koc S, Lu G (2021) Genetic imaging of neuroinflammation in Parkinson\u2019s disease: recent advancements. Front Cell Dev Biol 9:1\u201317. https:\/\/doi.org\/10.3389\/fcell.2021.655819","journal-title":"Front Cell Dev Biol"},{"key":"1549_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102186","volume":"48","author":"A Zeb","year":"2021","unstructured":"Zeb A, Choubey V, Gupta R et al (2021) A novel role of KEAP1\/PGAM5 complex: ROS sensor for inducing mitophagy. Redox Biol 48:102186. https:\/\/doi.org\/10.1016\/j.redox.2021.102186","journal-title":"Redox Biol"},{"key":"1549_CR98","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1080\/15548627.2021.2024702","volume":"18","author":"A Zeb","year":"2022","unstructured":"Zeb A, Choubey V, Gupta R et al (2022) Negative feedback system to maintain cell ROS homeostasis: KEAP1-PGAM5 complex senses mitochondrially generated ROS to induce mitophagy. Autophagy 18:2249\u20132251. https:\/\/doi.org\/10.1080\/15548627.2021.2024702","journal-title":"Autophagy"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01549-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T12:09:48Z","timestamp":1726920588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01549-1","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"12 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"NA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"NA.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}